Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer.
Avinash D KhadelaBhavin VyasMustakim MansuriDipen SurejaKunjan BodiwalaPublished in: Journal of the Egyptian National Cancer Institute (2023)
The three-drug therapy consisting of cetuximab, cisplatin, and paclitaxel has shown significant improvement in patients' QALYs compared to two-drug regimens of cetuximab and cisplatin. Thus, if the therapy consisted of three-drug regimen is used instead of two-drug regimen, it will have a positive impact on humanistic outcome in recurrent or metastatic HNC patients.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- peritoneal dialysis
- small cell lung cancer
- metastatic colorectal cancer
- prognostic factors
- locally advanced
- stem cells
- patient reported outcomes
- emergency department
- adverse drug
- radiation therapy
- cell therapy
- smoking cessation